Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | SCD | O00767 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3951369 | 0.98 | SLC6A2 (0.53) | SLC6A2SLC6A3HTR1ASLC6A4HTR2C | |
| SCHEMBL1782071 | 0.87 | HTR1A (0.58) | SLC6A2SLC6A3HTR1ASLC6A4HTR2C | |
| SCHEMBL7888184 | 0.87 | HTR1A (0.58) | SLC6A2SLC6A3HTR1ASLC6A4HTR2C | |
| SCHEMBL2819314 | 0.87 | HTR1A (0.58) | SLC6A2SLC6A3HTR1ASLC6A4HTR2C | |
| Hydrochloric Acid SCHEMBL2947998 | 0.85 | HTR1A (0.57) | SLC6A2SLC6A3HTR1ASLC6A4HTR2C | |
| SCHEMBL14957434 | 0.85 | SLC6A2 (0.66) | SLC6A2SLC6A3HTR1ASLC6A4HTR2C | |
| SCHEMBL83377 | 0.83 | HRH1 (0.57) | SLC6A2SLC6A3HTR1ASLC6A4HTR2C | |
| SCHEMBL3107107 | 0.82 | SLC6A2 (0.53) | SLC6A2SLC6A3HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL473008 | 0.81 | HRH1 (0.55) | SLC6A2SLC6A3HTR1ASLC6A4HTR2C | |
| SCHEMBL15627271 | 0.81 | SCD (0.45) | SLC6A2SLC6A3SLC6A4SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| CN-116507613-A | Bispecific antagonists of retinol binding protein 4 which stabilize transthyretin tetramer, their preparation and use in the treatment of common age-related complications | 纽约哥伦比亚大学理事会 | 2023-07-28 | — | — | CN | disclosed |
| EP-4181909-A2 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | The Trustees Of Columbia University In The City Of New York (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022020305-A2 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-2462121-B1 | DERIVATIVES OF 2H PYRIDAZIN-3-ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PF MEDICAMENT (FR) | 2015-02-18 | — | — | EP | disclosed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| EP-0102740-B1 | N-FORMYL AND N-HYDROXYMETHYL-3-PHENOXY-1-AZETIDINECARBOXAMIDES AND THEIR PREPARATION AND USE | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-11-05 | — | — | EP | disclosed |
| EP-0102194-B1 | 3-PHENOXY-1-AZETIDINECARBOXAMIDES AND THEIR USE AND PREPARATION | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-10-22 | — | — | EP | disclosed |
| EP-0194112-A1 | 3-Aryl-oxyazetidinecarboxamides having anti-muscle tension, anti-muscle spasticity, anticonvulsant and antiepilectic activity | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-09-10 | — | — | EP | disclosed |
| US-4594189-A | Process for preparing 3-phenoxy-1-azetidines and carboxamide derivatives | A. H. ROBINS COMPANY, INC. (US) | 1986-06-10 | — | — | US | disclosed |
| US-4571393-A | ANTICONVULSANT TREATMENT FOR MAMMALS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-02-18 | — | — | US | disclosed |
| US-4505907-A | ANTICONVULSANTS | A. H. ROBINS COMPANY, INC. (US) | 1985-03-19 | — | — | US | disclosed |
| EP-0131435-A1 | Process for preparing 3-phenoxy-1-azetidines and carboxamide derivatives | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-01-16 | — | — | EP | disclosed |
| EP-0102740-A1 | N-formyl and n-hydroxymethyl-3-phenoxy-1-azetidinecarboxamides and their preparation and use | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-03-14 | — | — | EP | disclosed |
| EP-0102194-A1 | 3-Phenoxy-1-azetidinecarboxamides and their use and preparation | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-03-07 | — | — | EP | disclosed |
| US-4226861-A | ANTICONVULSANTS | A. H. ROBINS COMPANY, INC. (US) | 1980-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | SCD, SCD5, CYP2S1 | SLC6A2 3488/4885SLC6A3 3482/4885HTR1A 591/4885 |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, RBP4, RBP1 | SLC6A2 1380/4885SLC6A3 993/4885HTR1A 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.